Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40(2):244–52.

Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, et al. New prostate cancer grade grouping system predicts survival after radical prostatectomy. Hum Pathol. 2018;75:159–66.

Article  PubMed  Google Scholar 

Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001;32(1):74–80.

Article  PubMed  Google Scholar 

Melia J, Moseley R, Ball RY, Griffiths DF, Grigor K, Harnden P, et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology. 2006;48(6):644–54.

Article  CAS  PubMed  Google Scholar 

Ozkan TA, Eruyar AT, Cebeci OO, Memik O, Ozcan L, Kuskonmaz I. Interobserver variability in Gleason histological grading of prostate cancer. Scand J Urol. 2016;50(6):420–4.

Article  CAS  PubMed  Google Scholar 

Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Comperat E, et al. Standardization of Gleason grading among 337 European pathologists. Histopathology. 2013;62(2):247–56.

Article  PubMed  Google Scholar 

Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.

Article  Google Scholar 

Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580(7801):93–9.

Article  CAS  PubMed  Google Scholar 

Stelloo S, Nevedomskaya E, Kim Y, Schuurman K, Valle-Encinas E, Lobo J, et al. Integrative epigenetic taxonomy of primary prostate cancer. Nat Commun. 2018;9(1):4900.

Article  PubMed  PubMed Central  Google Scholar 

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541(7637):359–64.

Article  CAS  PubMed  Google Scholar 

Charmpi K, Guo T, Zhong Q, Wagner U, Sun R, Toussaint NC, et al. Convergent network effects along the axis of gene expression during prostate cancer progression. Genome Biol. 2020;21(1):302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, et al. The proteogenomic landscape of curable prostate cancer. Cancer Cell. 2019;35(3):414-27 e6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of hbv-related hepatocellular carcinoma. Cell. 2019;179(2):561-77 e22.

Article  CAS  PubMed  Google Scholar 

Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182(1):245-61 e17.

Article  CAS  PubMed  Google Scholar 

Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019;567(7747):257–61.

Article  CAS  PubMed  Google Scholar 

Gao J, He J, Zhang F, Xiao Q, Cai X, Yi X, et al. Integration of protein context improves protein-based COVID-19 patient stratification. Clin Proteomics. 2022;19(1):31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo T, Kouvonen P, Koh CC, Gillet LC, Wolski WE, Rost HL, et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat Med. 2015;21(4):407–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai X, Ge W, Yi X, Sun R, Zhu J, Lu C, et al. PulseDIA: data-independent acquisition mass spectrometry using multi-injection pulsed gas-phase fractionation. J Proteome Res. 2021;20(1):279–88.

Article  CAS  PubMed  Google Scholar 

Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical validation of the oncotype DX prostate cancer assay—a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics. 2013;14:690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iglesias-Gato D, Wikstrom P, Tyanova S, Lavallee C, Thysell E, Carlsson J, et al. The proteome of primary prostate cancer. Eur Urol. 2016;69(5):942–52.

Article  CAS  PubMed  Google Scholar 

Kumar L, Matthias EF. Mfuzz: a software package for soft clustering of microarray data. Bioinformation. 2007;2(1):5–7.

Article  PubMed  PubMed Central  Google Scholar 

Chakravarthi B, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, et al. miR-34a regulates expression of the stathmin-1 oncoprotein and prostate cancer progression. Mol Cancer Res. 2018;16(7):1125–37.

Article  CAS  PubMed  Google Scholar 

Yamada Y, Nishikawa R, Kato M, Okato A, Arai T, Kojima S, et al. Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis. J Hum Genet. 2018;63(2):195–205.

Article  CAS  PubMed  Google Scholar 

Koh CM, Gurel B, Sutcliffe S, Aryee MJ, Schultz D, Iwata T, et al. Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol. 2011;178(4):1824–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsunaga S, Takata H, Morimoto A, Hayashihara K, Higashi T, Akatsuchi K, et al. RBMX: a regulator for maintenance and centromeric protection of sister chromatid cohesion. Cell Rep. 2012;1(4):299–308.

Article  CAS  PubMed  Google Scholar 

Marrocco I, Altieri F, Rubini E, Paglia G, Chichiarelli S, Giamogante F, et al. Shmt2: a Stat3 signaling new player in prostate cancer energy metabolism. Cells. 2019;8(9):1048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim J, Mizokami A, Shin M, Izumi K, Konaka H, Kadono Y, et al. SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. Anticancer Res. 2014;34(6):2821–31.

CAS  PubMed  Google Scholar 

Andor N, Graham TA, Jansen M, Xia LC, Aktipis CA, Petritsch C, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105–13.

Article  CAS  PubMed  Google Scholar 

Takahashi S, Suzuki S, Inaguma S, Ikeda Y, Cho YM, Hayashi N, et al. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers. Prostate. 2003;54(3):187–93.

Article  CAS  PubMed  Google Scholar 

Minner S, Hager D, Steurer S, Hoflmayer D, Tsourlakis MC, Moller-Koop C, et al. Down-regulation of S100A8 is an independent predictor of PSA recurrence in prostate cancer treated by radical prostatectomy. Neoplasia. 2019;21(9):872–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang JH, Zhang L, Huang ST, Xu J, Zhou Y, Yu XJ, et al. Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma. PLoS ONE. 2017;12(4): e0175280.

Article  PubMed  PubMed Central  Google Scholar 

Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 2006;66(24):11897–906.

Article  CAS  PubMed  Google Scholar 

Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Latonen L, Afyounian E, Jylha A, Nattinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9(1):1176.

Article  PubMed  PubMed Central  Google Scholar 

Meng J, Lu X, Jin C, Zhou Y, Ge Q, Zhou J, et al. Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clin Transl Med. 2021;11(12): e655.

Article  CAS